n°186

October 2017

Issue Contents
Editorial

Free  Medical schools and conflicts of interest

p.227

Marketing Authorisations

Naloxegol (Moventig°) and opioid-induced constipation

p.229-231
Its abdominal adverse effects are probably as troublesome as constipation

Ticagrelor (Brilique°) in patients with a history of myocardial infarction

p.231-233
In addition to aspirin: no more beneficial than aspirin alone

Guanfacine (Intuniv°) and attention deficit hyperactivity disorder

p.233-236
Excessive drowsiness and serious cardiovascular harms

Pitolisant (Wakix°) and narcolepsy

p.236-237
No better than existing drugs

Selexipag (Uptravi°) and pulmonary arterial hypertension

p.237-238
Not acceptable

INN Common stem: -racetam

p.238

Adverse Effects

SSRI antidepressants and pregnancy: a link with autism?

p.239-240

Free  Metformin in patients with moderate renal impairment: reduce the dose

p.241

Clopidogrel: increases the adverse effects of paclitaxel

p.242

Mefenamic acid: convulsions in cases of overdose

p.242

Gliptins and pancreatitis

p.243

Nivolumab, pembrolizumab and transplant rejection

p.243

Reviews

Atrial fibrillation

p.244-245
Aspirin: no proven value in stroke prevention

Inset. Atrial fibrillation: assessing thrombotic risk using the CHA2DS2-VASc score

p.245

Diabetes and liraglutide

p.246-247
Very tenuous results from the Leader trial

Distal deep vein thrombosis

p.247
When confined to the calf, do not routinely use heparin

Outlook

Free  Tackling conflicts of interest

p.248

Dangerous excipients

p.249-250
Too little information

Private patents and public health

p.251
Changing intellectual property rules for access to medicines

Free  2017 Prescrire Prize

p.252
The 2017 Prescrire Prize has been awarded to 4 works

Masthead

Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe